Galmed与特拉维夫大学达成合作，评估Scd1抑制剂Aramchol作为转移性脑癌靶向疗法

美股速递04-14 19:30

Galmed Pharmaceuticals Ltd.（纳斯达克代码：GLMD）近日宣布与以色列特拉维夫大学签署一项合作协议，双方将共同研究其开发的硬脂酰辅酶A去饱和酶1（Scd1）抑制剂Aramchol在转移性脑癌治疗领域的靶向应用潜力。该合作旨在通过临床前模型验证Aramchol调节肿瘤代谢通路的作用机制，探索其对血脑屏障的穿透性及抑制癌细胞转移的效果。若研究取得积极成果，这款原本用于非酒精性脂肪性肝炎治疗的药物或将为晚期脑癌患者提供新的治疗方向。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1187957944?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-14 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187957944","market":"us","top_or_hot":-1,"title":"Galmed与特拉维夫大学达成合作，评估Scd1抑制剂Aramchol作为转移性脑癌靶向疗法","media":"美股速递","content":"<p>Galmed Pharmaceuticals Ltd.（纳斯达克代码：GLMD）近日宣布与以色列特拉维夫大学签署一项合作协议，双方将共同研究其开发的硬脂酰辅酶A去饱和酶1（Scd1）抑制剂Aramchol在转移性脑癌治疗领域的靶向应用潜力。该合作旨在通过临床前模型验证Aramchol调节肿瘤代谢通路的作用机制，探索其对血脑屏障的穿透性及抑制癌细胞转移的效果。若研究取得积极成果，这款原本用于非酒精性脂肪性肝炎治疗的药物或将为晚期脑癌患者提供新的治疗方向。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Galmed与特拉维夫大学达成合作，评估Scd1抑制剂Aramchol作为转移性脑癌靶向疗法</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGalmed与特拉维夫大学达成合作，评估Scd1抑制剂Aramchol作为转移性脑癌靶向疗法\n</h2>\n\n<h4 class=\"meta\">\n\n2026-04-14 19:30 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Galmed Pharmaceuticals Ltd.（纳斯达克代码：GLMD）近日宣布与以色列特拉维夫大学签署一项合作协议，双方将共同研究其开发的硬脂酰辅酶A去饱和酶1（Scd1）抑制剂Aramchol在转移性脑癌治疗领域的靶向应用潜力。该合作旨在通过临床前模型验证Aramchol调节肿瘤代谢通路的作用机制，探索其对血脑屏障的穿透性及抑制癌细胞转移的效果。若研究取得积极成果，这款原本用于非酒精性...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1187957944","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187957944","pubTimestamp":1776166246,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Galmed Pharmaceuticals Ltd.（纳斯达克代码：GLMD）近日宣布与以色列特拉维夫大学签署一项合作协议，双方将共同研究其开发的硬脂酰辅酶A去饱和酶1（Scd1）抑制剂Aramchol在转移性脑癌治疗领域的靶向应用潜力。该合作旨在通过临床前模型验证Aramchol调节肿瘤代谢通路的作用机制，探索其对血脑屏障的穿透性及抑制癌细胞转移的效果。若研究取得积极成果，这款原本用于非酒精性脂肪性肝炎治疗的药物或将为晚期脑癌患者提供新的治疗方向。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","GLMD":"Galmed Pharmaceuticals Ltd."},"translate_title":"Galmed reaches collaboration with Tel Aviv University to evaluate Scd1 inhibitor Aramchol as a targeted therapy for metastatic brain cancer","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLMD":1},"content_text":"Galmed Pharmaceuticals Ltd.（纳斯达克代码：GLMD）近日宣布与以色列特拉维夫大学签署一项合作协议，双方将共同研究其开发的硬脂酰辅酶A去饱和酶1（Scd1）抑制剂Aramchol在转移性脑癌治疗领域的靶向应用潜力。该合作旨在通过临床前模型验证Aramchol调节肿瘤代谢通路的作用机制，探索其对血脑屏障的穿透性及抑制癌细胞转移的效果。若研究取得积极成果，这款原本用于非酒精性脂肪性肝炎治疗的药物或将为晚期脑癌患者提供新的治疗方向。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187957944","isCrawlerRequest":true}